Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5127]

Inhibiting the immune system’s natural response may boost benefits and...

Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA

Inhibiting the immune system’s natural response may boost benefits and sustainability of CAR T therapy ( Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA )

Ibrutinib alone and in combination with rituximab for older patients with...

Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Centre...

Ibrutinib alone and in combination with rituximab for older patients with chronic lymphocytic leukaemia ( Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Centre, Columbus, USA )

Improving toxicity and outcomes by taking ibrutinib during and after CAR T-cell...

Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA

$Improving toxicity and outcomes by taking ibrutinib during and after CAR T-cell therapy for relapsed and/or refractory CLL ( Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA )$

Latest analysis of the ELIANA trial for acute lymphocytic leukaemia

Dr Stephan Grupp - University of Pennsylvania, Philadelphia, USA

Latest analysis of the ELIANA trial for acute lymphocytic leukaemia ( Dr Stephan Grupp - University of Pennsylvania, Philadelphia, USA )

CD19-directed CAR T-cell therapy for patients with relapsed B-cell acute...

Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA

CD19-directed CAR T-cell therapy for patients with relapsed B-cell acute lymphocytic leukaemia ( Dr Shannon Maude - Children’s Hospital of Philadelphia, Philadelphia, USA )

Latest results from JULIET: Tisagenlecleucel in adults with DLBCL

Dr Richard Maziarz - Oregon Health & Science Knight Cancer Institute, Portland...

Latest results from JULIET: Tisagenlecleucel in adults with DLBCL ( Dr Richard Maziarz - Oregon Health & Science Knight Cancer Institute, Portland, USA )

CAR T-Cell therapy with concurrent ibrutinib for chronic lymphocytic leukaemia

Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA

CAR T-Cell therapy with concurrent ibrutinib for chronic lymphocytic leukaemia ( Dr Jordan Gauthier - Fred Hutchinson Cancer Research Centre, Seattle, USA )

Stem cell transplant after CAR T-cell therapy reduces relapses in acute...

Dr Corinne Summers - Seattle Children's Hospital, Seattle, USA

Stem cell transplant after CAR T-cell therapy reduces relapses in acute lymphocytic leukaemia ( Dr Corinne Summers - Seattle Children's Hospital, Seattle, USA )

Four cycles of chemotherapy as effective as six for diffuse large B-Cell...

Dr Viola Pöschel - Saarland University Medical School, Homburg, Germany

Four cycles of chemotherapy as effective as six for diffuse large B-Cell lymphoma ( Dr Viola Pöschel - Saarland University Medical School, Homburg, Germany )

Luspatercept reduces need for blood transfusions in beta thalassemia and MDS

Dr Maria Domenica Cappellini - University of Milan, Milan, Italy

Luspatercept reduces need for blood transfusions in beta thalassemia and MDS ( Dr Maria Domenica Cappellini - University of Milan, Milan, Italy )

Ibrutinib outperforms chemoimmunotherapy in older patients with chronic...

Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Center...

Ibrutinib outperforms chemoimmunotherapy in older patients with chronic lymphocytic leukaemia ( Dr Jennifer Woyach - The Ohio State University Comprehensive Cancer Center, Columbus, USA )

Results from the MEDALIST trial for patients with anaemia in MDS

Dr Alan List - Moffitt Cancer Center, Tampa, USA

Results from the MEDALIST trial for patients with anaemia in MDS ( Dr Alan List - Moffitt Cancer Center, Tampa, USA )

More from ecancer